Clinical trials: Schizophrenia
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
The Management of Schizophrenia in Clinical Practice (MOSAIC)
This study is a disease-based registry designed to follow patients with a DSM-IV-TR (Diagnostic and Statistic Manual of Mental Disorders, Text Revision) diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform…
- Trial name
- NCT01746134
- Where
- 44 sites in United States
- Volunteers
- 557 people
- Sponsor
- Genentech, Inc.
Schizophrenia, Alzheimer's Disease Psychosis
A Food Effect Study of LY03020 in Healthy Subjects
This is a randomized, open-label, single-dose, two-period, crossover study to assess the food effect on pharmacokinetics (PK) and safety of LY03020 in healthy subjects.
- Trial name
- NCT07292233
- Testing
- LY03020
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
This clinical study will compare the equivalence of two products containing Paliperidone 100 mg in the form of a prolonged release suspension for injection in patients affected by schizophrenia who are already receiving this…
- Trial name
- NCT03425552
- Testing
- Paliperidone
- Where
- 3 sites in Jordan
- Volunteers
- 70 people
- Sponsor
- Pharmathen S.A.
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of flexible-doses paliperidone ER (3 to 12 mg as needed) compared with placebo over 3 weeks in patients with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00309699
- Testing
- Quetiapine, Paliperidone ER
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 493 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study…
- Trial name
- NCT07459647
- Testing
- ML-007C-MA
- Where
- 45 sites in United States
- Volunteers
- 500 people
- Sponsor
- MapLight Therapeutics
Schizophrenia
VLT-015 in Patients With Schizophrenia
15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses.
- Trial name
- VLT-015 (NCT05516121)
- Testing
- VLT-015
- Where
- 2 sites in Russia
- Volunteers
- 15 people
- Sponsor
- CF Pharma, LLC
Schizophrenia, Bipolar I Disorder
Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine Depot in subjects eligible for treatment with oral…
- Conditions
- Schizophrenia, Bipolar I Disorder, Major Depressive Disorder
- Trial name
- NCT07185815
- Testing
- Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day
- Where
- 6 sites in India, Israel
- Volunteers
- 24 people
- Sponsor
- Mapi Pharma Ltd.
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
Acute Agitation
A Study of Olanzapine in Patients With Acute Agitation
The purpose of this study is to assess the efficacy and safety of intramuscular olanzapine for the treatment of acute agitation associated with schizophrenia and bipolar I mania.
- Trial name
- NCT05803642
- Testing
- Olanzapine, Haloperidol
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Schizophrenia
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.
- Trial name
- HP-3070 (NCT02876900)
- Testing
- Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch
- Where
- United States
- Volunteers
- 617 people
- Sponsor
- Noven Pharmaceuticals, Inc.
Schizophrenia
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.
- Trial name
- CRESSOB (NCT00584519)
- Testing
- non-interventional
- Volunteers
- 430 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizo Affective Disorder, Schizophrenia
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients
- Conditions
- Schizo Affective Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03751488
- Testing
- LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple, ascending doses of PF-04958242 administered orally to psychiatrically stable subjects with schizophrenia receiving antipsychotic and adjunctive medication.
- Trial name
- NCT01518894
- Testing
- PF-04958242
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Biogen
Schizophrenia, Bipolar I Disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
- Trial name
- NCT05303064
- Testing
- OLZ/SAM, Olanzapine
- Where
- 47 sites in United States, Argentina and 3 more
- Volunteers
- 220 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.
- Trial name
- NCT02453893
- Testing
- Iloperidone, Risperidone
- Where
- China
- Volunteers
- 288 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
The purpose of this study is to explore the efficacy of paliperidone palmitate administered as a once monthly injection in patients with an acute exacerbation of schizophrenia.
- Trial name
- NCT01448720
- Testing
- Paliperidone palmitate
- Where
- 12 sites in Brazil, Colombia and 1 more
- Volunteers
- 142 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
First Episode Schizophrenia, Social Function
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
This is an open label, multi-center study to explore the effects on social functions of blonanserin in first episode schizophrenia patients
- Conditions
- First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin
- Trial name
- NCT03784222
- Testing
- Blonanserin, MRI and serum BDNF
- Where
- 8 sites in China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.